Disposition of 278 shares by Gordon Brooks of Eli Lilly subject to Rule 16b-3
| PHPIX Fund | USD 27.85 0.00 0.00% |
Slightly above 55% of Pharmaceuticals Ultrasector's investor base is interested to short. The analysis of overall sentiment of trading Pharmaceuticals Ultrasector Profund mutual fund suggests that many investors are impartial at this time. Pharmaceuticals Ultrasector's investing sentiment can be driven by a variety of factors including economic data, Pharmaceuticals Ultrasector's earnings reports, geopolitical events, and overall market trends.
Pharmaceuticals |
Filed transaction by Eli Lilly and Officer: Interim Cfo, Group Vp. Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
Read at bizjournals.com
 |
Pharmaceuticals Ultrasector Fundamental Analysis
We analyze Pharmaceuticals Ultrasector's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Pharmaceuticals Ultrasector using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Pharmaceuticals Ultrasector based on its fundamental data. In general, a quantitative approach, as applied to this mutual fund, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Total Asset
Total Asset Comparative Analysis
Pharmaceuticals Ultrasector is currently under evaluation in total asset among similar funds. Total Asset is everything that a business owns. It is the sum of current and long-term assets owned by a firm at a given time. These assets are listed on a balance sheet and typically valued based on their purchasing prices, not the current market value.
Pharmaceuticals Ultrasector Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Pharmaceuticals Ultrasector mutual fund to make a market-neutral strategy. Peer analysis of Pharmaceuticals Ultrasector could also be used in its relative valuation, which is a method of valuing Pharmaceuticals Ultrasector by comparing valuation metrics with similar companies.
Peers
Pharmaceuticals Ultrasector Related Equities
| DSCPX | Davenport Small | 0.58 | ||||
| LIGFX | Lord Abbett | 0.00 | ||||
| DTICX | Delaware Limited-term | 0.00 | ||||
| PLKTX | Principal Lifetime | 0.00 | ||||
| MDSKX | Blackrock | 0.00 | ||||
| NSIDX | Northern Small | 0.06 | ||||
| PASVX | T Rowe | 0.23 |
Other Information on Investing in Pharmaceuticals Mutual Fund
Pharmaceuticals Ultrasector financial ratios help investors to determine whether Pharmaceuticals Mutual Fund is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Pharmaceuticals with respect to the benefits of owning Pharmaceuticals Ultrasector security.
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
| Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities |